Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
Home Headlines Germany’s vaccine panel says one COVID shot enough for children
Headlines

Germany’s vaccine panel says one COVID shot enough for children

by jcp May 24, 2022
May 24, 2022
gawdo

By Patricia Weiss and Ludwig Burger

FRANKFURT (Reuters) -Germany’s vaccine advisory panel on Tuesday said one COVID-19 shot was enough for healthy five- to 11-year-olds because most of them had already undergone an infection, maintaining its cautious approach.

The view by the panel of 18 appointees, known as STIKO, contrasts with European Union regulators’ approval for a two-shot regimen in that age group. U.S. regulators last week even authorized a third, booster shot for the group.

“For children we have to assume that the rate of spreading of the infection is the highest. That’s why it’s reasonable to administer only one vaccination,” STIKO panel member Martin Terhardt told a media briefing.

The expert panel’s previous view on the age group, published in December, was to limit vaccinations to those at risk of developing severe COVID-19 or those living with an at-risk person, drawing criticism at the time for not keeping up with the of pace of the coronavirus.

German Health Minister Karl Lauterbach said STIKO’s move had his full backing.

“I hope that the vaccine will be well accepted but we must not exert pressure,” he added.

Children at risk of developing severe COVID-19 should get three shots and those living with an at-risk person should get two, the STIKO experts added on Tuesday.

About 22% of five- to 11-year-old children in Germany have so far received at least one COVID shot. Within the age group of five to nine years, tracked by the European Centre for Disease Prevention and Control (ECDC), a higher vaccination rate has been registered in Spain, Portugal, Denmark and Austria.

STIKO did not highlight any disadvantages of giving more shots. Instead it said the risk of heart inflammation from a vaccination appeared to be markedly lower for younger children than in youngsters above 12 years old or young adults.

An estimated 77.5% of five to 11-year-olds in Germany had already acquired some immunity against the virus either through known and undetected infections or via vaccination, the panel said in a document posted online.

STIKO said the preferred product was the paediatric version of BioNTech and Pfizer’s Comirnaty but Moderna’s shot was another option for those six years and older.

(Additional reporting by Riham Alkousaa in BerlinEditing by Madeline Chambers and Susan Fenton)

www.gawdo.com
Share on FacebookShare on TwitterShare on Linkedin
0 FacebookTwitterPinterestEmail
previous post
EU calls for Russia dialogue to unlock Ukraine food exports
next post
Finland, Sweden to send teams to Turkey to discuss NATO bids, Haavisto says

You may also like

Global food makers, retailers remain in crisis mode

June 22, 2022

UK inflation hits 40-year record, highest in G7

June 22, 2022

Spain readies new tax on electric utilities’ profits

June 21, 2022
Editorial & Advertiser disclosureEditorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gawdo.com
https://www.gawdo.com
  • About us
  • Advertising & Terms of Use
  • Contact Us
  • Privacy Policy

@2021 - All Right Reserved.


Back To Top
Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT